Irvine3 Labs, Department Biomedical Sciences, CH-PE University.
Phytother Res. 2013 Oct;27(10):1572-8. doi: 10.1002/ptr.4883. Epub 2013 Jan 28.
This open, controlled study evaluated the effects of 6 month supplementation with Pycnogenol® maritime pine bark extract on health risk factors in subjects with metabolic syndrome. Pycnogenol® was used with the aim of improving risk factors associated with metabolic syndrome, central obesity, elevated triglycerides (TG), low HDL cholesterol, high blood pressure and fasting blood glucose. Sixty-four subjects (range 45-55 years) presenting with all five risk factors of metabolic syndrome were included, and Pycnogenol® was administered for 6 months. A group of 66 equivalent subjects were followed up as controls. In the 6-month study Pycnogenol® supplementation 150 mg/day decreased waist circumference, TG levels, blood pressure and increased the HDL cholesterol levels in subjects. Pycnogenol lowered fasting glucose from baseline 123 ± 8.6 mg/dl to 106.4 ± 5.3 after 3 months and to 105.3 ± 2.5 at the end of the study (p < 0.05 vs controls). Men's waist circumference decreased with Pycnogenol from 106.2 ± 2.2 cm to 98.8 ± 2.3 cm and to 98.3 ± 2.1 after 3 and 6 months. Women's waist decreased from 90.9 ± 1.6 cm to 84.6 ± 2.1 cm and to 83.6 ± 2.2 cm after 3 and 6 months. Both genders waist circumference reduction was significant as compared to controls at both time points. In addition, plasma free radicals decrease in the Pycnogenol group was more effective than in the control group (-34.6%; p < 0.05). In conclusion, this study indicates a role for Pycnogenol® for improving health risk factors in subjects with metabolic syndrome.
这项开放、对照研究评估了 6 个月补充 Pycnogenol® 马尾松树皮提取物对代谢综合征患者健康风险因素的影响。使用 Pycnogenol® 的目的是改善与代谢综合征、中心性肥胖、甘油三酯升高 (TG)、低 HDL 胆固醇、高血压和空腹血糖相关的风险因素。共纳入 64 名（年龄 45-55 岁）存在代谢综合征所有 5 项风险因素的患者，并给予 Pycnogenol® 治疗 6 个月。66 名具有相同特征的患者作为对照组进行随访。在 6 个月的研究中，Pycnogenol® 补充剂 150mg/天可降低腰围、TG 水平、血压，并升高 HDL 胆固醇水平。Pycnogenol®可使空腹血糖从基线的 123±8.6mg/dl 降低至 3 个月时的 106.4±5.3mg/dl 和研究结束时的 105.3±2.5mg/dl（与对照组相比，p<0.05）。男性腰围在服用 Pycnogenol®后从 106.2±2.2cm 降至 98.8±2.3cm 和 98.3±2.1cm，3 个月和 6 个月时与对照组相比均显著降低。女性腰围从 90.9±1.6cm 降至 84.6±2.1cm 和 83.6±2.2cm，3 个月和 6 个月时与对照组相比均显著降低。与对照组相比，两组患者的腰围减少均有统计学意义。此外，Pycnogenol®组的血浆自由基减少更有效（-34.6%；p<0.05）。总之，这项研究表明 Pycnogenol®可改善代谢综合征患者的健康风险因素。
